Eribulin Mesylate

USDailyMed:Eribulin AU:D L01XX41(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyRx-only 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one 253128-41-5Y 11354606 DB08871Y 24721813Y LR24G6354G D08914 CHEBI:63587 ChEMBL1683590Y DTXSID101009321 Interactive image CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1YKey:UFNVPOGXISZXJD-JBQZKEIOSA-NY Eribulin, sold under the brand nameHalavenamong others, is an intravenously administeredanti-cancer medicationused to treat certain patients withbreast cancerandliposarcoma.Eribulin was approved for medical use in the United States in November 2010,the European Union in March 2011,Japan in April 2011,and Canada in December 2011.It is available in some jurisdictions as ageneric medication.